A Baltimore factory that had to be shut down by the U.S. Food and Drug Administration (FDA) in April will return to operation soon.
Emergent BioSolutions, which was contracted to manufacture the Johnson & Johnson and AstraZeneca vaccines at the facility, confirmed the news on Thursday to The Wall Street Journal.
In April, J&J had to trash millions of doses of its vaccine after the plant mixed-up ingredients with those of the AstraZeneca vaccine.
After a thorough review, the FDA found the vaccines were produced in unsanitary conditions and that workers were not properly trained.
Emergent did not say exactly when production will resume at the factory.
A Baltimore factory that was forced to close after producing contaminated doses of the Johnson & Johnson vaccine is slated to reopen soon
The plant (above) forced to close after Johnson & Johnson vaccines were contaminated with AstraZeneca vaccine ingredients, and a further investigation found unsanitary conditions
'Based upon our current observations of the implemented corrective actions, FDA does not object to the resumption of manufacturing,' the FDA wrote to Emergent in a letter obtained by The Journal.
Up to 30 million doses produced by the plant before the closure could potentially be cleared by the FDA for use.
In June, however, the FDA ordered millions of doses produced at that factory be discarded due to the contamination.
AstraZeneca vaccines produced at the factory have not yet been cleared for use.
Once the factory reopens and is operating at full capacity, up to 120 million doses could be produced every month.
Since April, FDA inspectors have
